Amplia Therapeutics halted recruitment in its Phase II Amplicity trial in advanced pancreatic cancer after three dose-limiting toxicities tied to the modified FOLFIRINOX chemotherapy backbone combined with narmafotinib (AMP-945). The company said no dose-limiting toxicities were reported with narmafotinib alone and that patients already enrolled will remain on study. Amplia indicated it is exploring less toxic chemotherapy regimens as it reconsiders the combination strategy. The change highlights the ongoing challenge of balancing efficacy and tolerability in pancreatic cancer combinations, particularly when adding targeted agents to intensive chemotherapy backbones. For trial participants and competitors, the decision underscores how quickly regimen-specific safety signals can reshape Phase II trajectories even when targeted agents show biological rationale.